Goldman Sachs Starts Arcus Biosciences (RCUS) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Leerink Partners Starts Arcus Biosciences (RCUS) at Outperform
April 9, 2018 6:42 AM EDTLeerink Partners initiates coverage on Arcus Biosciences (NYSE: RCUS) with a Outperform rating and a price target of $21.00.
Analyst Geoffrey Porges commented, "All in on Adenosine but Still Early."
For an analyst ratings summary and ratings history on Arcus Biosciences... More
Citi Starts Arcus Biosciences (RCUS) at Buy
April 9, 2018 4:10 AM EDTCiti initiates coverage on Arcus Biosciences (NYSE: RCUS) with a Buy rating and a price target of $25.00.
Analyst Robyn Karnauskas sees an attractive risk/return profile. The analyst comments "Arcus is developing I/O drugs for the treatment of solid tumors. While... More
